Aurinia Pharmaceuticals (AUPH) Common Equity (2017 - 2026)

Aurinia Pharmaceuticals (AUPH) has 10 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Common Equity rose 210.3% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 210.3% YoY) and the FY2025 annual result came in at $581.3 million, up 54.0% from the prior year.
• Common Equity advanced to $1.1 billion in Q1 2026, from $581.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.1 billion in Q3 2025 to a low of $335.3 million in Q2 2025.
• A 5-year average of $483.1 million and a median of $391.9 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity slipped 15.37% — and 2026, when it soared 210.3%.
• Tracing AUPH's Common Equity over 5 years: stood at $405.4 million in 2022, then fell by 6.78% to $378.0 million in 2023, then declined by 0.13% to $377.5 million in 2024, then soared by 54.0% to $581.3 million in 2025, then jumped by 86.92% to $1.1 billion in 2026.
• The last three Common Equity figures came in at $1.1 billion (Q1 2026), $581.3 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.